ALTA3263 for advanced KRAS-mutated solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a KRAS mutation that was found by a standard genetic test.
- Your cancer must be advanced (spread or can't be removed) and you've tried other treatments or can't take them.
- You must be able to take care of yourself (up and about more than 50% of the time).
- Your organs (kidneys, liver, etc.) must work well enough.
- You cannot have taken a KRAS-targeting drug before (like sotorasib or adagrasib), and you must be able to swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests an experimental drug called LT-010391 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The drug is designed to target this mutation, and the study aims to see if it can help when standard treatments are no longer working.
This trial tests an experimental pill, JAB-23E73, for people with advanced solid tumors that have a specific genetic change called KRAS. The drug may block the effects of this altered gene, potentially slowing or stopping tumor growth.
This trial tests a new pill called ASN-3186 for people with advanced solid tumors that haven't responded to standard treatments. The drug may work especially well if your cancer has certain DNA repair problems, like a BRCA mutation.
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.